ALNA - Allena Pharmaceuticals: Red Flags Abound And That Makes This A Difficult Call
Allena Pharmaceuticals (ALNA) is a micro-cap targeting a very specific niche indication called Hyperoxaluria, a metabolic disorder characterized by significantly elevated oxalate levels in the urine. Its entire pipeline is centered around various forms of this disease. Its lead drug candidate Reloxaliase is in the late stages targeting secondary enteric hyperoxaluria, and should be market ready by late 2020. The disease has no currently approved treatments, and only a few companies are working in the area. We used the IOMachine method to investigate.
The science
Excess oxalate in the urine can result from